Abstract
Get full access to this article
View all access options for this article.
References
1.
Musunuru
K
,
Grandinette
SA
,
Wang
X
, et al. Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease . 2025 . Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2504747 [Last accessed:
June 6 , 2025
].
2.
Lin
F
. ASGCT 2025: World’s First Patient Treated with Personalized CRISPR Therapy . Genetic Engineering & Biotechnology News . 2025 . Available from: https://www.genengnews.com/topics/genome-editing/asgct-2025-worlds-first-patient-treated-with-personalized-crispr-therapy/ [Last accessed:
June 6 , 2025
].
3.University of Pennsylvania . World’s first patient treated with personalized CRISPR gene editing therapy through CHOP and Penn Med collaboration . 2025 . Available from: https://penntoday.upenn.edu/news/penn-medicine-worlds-first-patient-treated-personalized-crispr-gene-editing-therapy-childrens-hospital [Last accessed:
June 6 , 2025
].
4.Rocket Pharma . Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease . 2025 . Available from: https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-provides-update-phase-2-clinical-trial-rp [Last accessed:
June 6 , 2025
].
5.
Davies
KA
,
Philippidis
A
. Cell and Gene Therapy Leaders Tell FDA: “Believe in American Solutions.” . Genetic Engineering & Biotechnology News . 2025 . Available from: https://www.genengnews.com/topics/genome-editing/cell-and-gene-therapy-leaders-tell-fda-believe-in-american-solutions/ [Last accessed:
June 7 , 2025
].
6.
REGENXBIO. REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million . 2025 . Available from: https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-strategic-royalty-monetization-agreement-250 [Last accessed:
June 10 , 2025
].
7.SpliceBio . SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines . 2025 . Available from: https://splice.bio/splicebio-secures-135-million-series-b-financing-to-advance-lead-program-sb-007-in-stargardt-disease-and-expand-pipeline-of-genetic-medicines/ [Last accessed:
June 11 , 2025
].
8.Sarepta Therapeutics . U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4 . 2025 . Available from: https://investorrelations.sarepta.com/news-releases/news-release-details/us-fda-grants-platform-technology-designation-viral-vector-used [Last accessed:
June 7 , 2025
].
9.
Dunleavy
K
. After holding out, bluebird bio investors get on board with sale to Carlyle, SK Capital . FiercePharma . 2025 . Available from: https://www.fiercepharma.com/pharma/after-holding-out-bluebird-bio-investors-get-board-sale-carlyle-sk-capital [Last accessed:
June 6 , 2025
].
10.Bluebird Bio . Bluebird Bio d Announces Completion of Acquisition by Carlyle and SK Capital . 2025 . Available from: https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-completion-acquisition-carlyle-and-sk [Last accessed:
June 6 , 2025
].